The researchers have developed two therapeutic "cocktails" to stop immune cells from overreacting to allergens. The cocktails inhibit key molecules (called ICOSL, OX40L, and CD30L) that they found ...

The cocktails inhibit key molecules (called ICOSL, OX40L, and CD30L) that they found allow specialized tissue-resident memory T cells to stay active and maintained in high numbers in tissues.

Navigator Medicines, Inc., a clinical-stage biotech company leading the advancement of biologics for targeted immune ...

Apogee Therapeutics, Inc. announced positive interim Phase 1 results for its novel OX40L antibody, APG990, which demonstrated a half-life of approximately 60 days and potential for infrequent dosing.

Poster Presentation Title: A First-in-Human Phase 1a Randomized, Double-Blind Single-Ascending Dose Study of NAV-240, an anti-OX40L/TNF-alpha Bispecific Antibody, in Healthy Volunteers Presenter ...

Butt and Mr. Farooq augment Navigator’s leadership team as the Company continues to advance NAV-240, a clinical-stage bispecific antibody targeting TNFα and OX40L, alongside a pipeline of OX40L ...

Navigator, which began its journey last year as a subsidiary of Sera Medicines, is working on NAV-240, a clinical-stage bispecific antibody against OX40L and TNFα that recently wrapped up a phase ...